JPWO2020227758A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020227758A5 JPWO2020227758A5 JP2021568406A JP2021568406A JPWO2020227758A5 JP WO2020227758 A5 JPWO2020227758 A5 JP WO2020227758A5 JP 2021568406 A JP2021568406 A JP 2021568406A JP 2021568406 A JP2021568406 A JP 2021568406A JP WO2020227758 A5 JPWO2020227758 A5 JP WO2020227758A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- rage
- mrna
- exon
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 claims description 47
- 239000002773 nucleotide Substances 0.000 claims description 42
- 108020004999 messenger RNA Proteins 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 6
- 229940035893 uracil Drugs 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 229940113082 thymine Drugs 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 46
- 238000012230 antisense oligonucleotides Methods 0.000 claims 46
- 108091034117 Oligonucleotide Proteins 0.000 claims 42
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 claims 24
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 claims 24
- 230000000295 complement effect Effects 0.000 claims 8
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 5
- 230000011987 methylation Effects 0.000 claims 2
- 238000007069 methylation reaction Methods 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000001175 peptic effect Effects 0.000 claims 1
- 208000017443 reproductive system disease Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061149A JP2025106369A (ja) | 2019-05-14 | 2025-04-02 | 終末糖化産物受容体ｒｎａのモジュレーター及び調節 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019901641A AU2019901641A0 (en) | 2019-05-14 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| AU2019901641 | 2019-05-14 | ||
| AU2019902095 | 2019-06-17 | ||
| AU2019902095A AU2019902095A0 (en) | 2019-06-17 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| AU2019902772 | 2019-08-02 | ||
| AU2019902772A AU2019902772A0 (en) | 2019-08-02 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| AU2019903900 | 2019-10-16 | ||
| AU2019903900A AU2019903900A0 (en) | 2019-10-16 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| PCT/AU2020/050449 WO2020227758A1 (en) | 2019-05-14 | 2020-05-07 | Modulators and modulation of the receptor for advanced glycation end-products rna |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061149A Division JP2025106369A (ja) | 2019-05-14 | 2025-04-02 | 終末糖化産物受容体ｒｎａのモジュレーター及び調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533358A JP2022533358A (ja) | 2022-07-22 |
| JP2022533358A5 JP2022533358A5 (https=) | 2023-08-15 |
| JPWO2020227758A5 true JPWO2020227758A5 (https=) | 2023-08-15 |
Family
ID=73290056
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568406A Pending JP2022533358A (ja) | 2019-05-14 | 2020-05-07 | 終末糖化産物受容体ｒｎａのモジュレーター及び調節 |
| JP2025061149A Pending JP2025106369A (ja) | 2019-05-14 | 2025-04-02 | 終末糖化産物受容体ｒｎａのモジュレーター及び調節 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061149A Pending JP2025106369A (ja) | 2019-05-14 | 2025-04-02 | 終末糖化産物受容体ｒｎａのモジュレーター及び調節 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11441148B2 (https=) |
| EP (1) | EP3969590A4 (https=) |
| JP (2) | JP2022533358A (https=) |
| KR (1) | KR20220009971A (https=) |
| CN (1) | CN114127288A (https=) |
| AU (2) | AU2020276337B2 (https=) |
| BR (1) | BR112021022714A2 (https=) |
| CA (1) | CA3140209A1 (https=) |
| IL (1) | IL288040A (https=) |
| MX (1) | MX2021013858A (https=) |
| SG (1) | SG11202112144RA (https=) |
| WO (1) | WO2020227758A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022533358A (ja) | 2019-05-14 | 2022-07-22 | モナシュ ユニバーシティ | 終末糖化産物受容体ｒｎａのモジュレーター及び調節 |
| WO2024229505A1 (en) * | 2023-05-05 | 2024-11-14 | RAGE Biotech Pty Ltd | Administration of oligonucleotides |
| AU2023447004A1 (en) * | 2023-05-05 | 2025-10-16 | RAGE Biotech Pty Ltd | Methods of monitoring splicing |
| KR20260027924A (ko) * | 2023-05-19 | 2026-03-03 | 레이지 바이오텍 피티와이 리미티드 | 연기 노출의 영향 최소화 방법 |
| KR20260027923A (ko) * | 2023-05-19 | 2026-03-03 | 레이지 바이오텍 피티와이 리미티드 | 폐 섬유증 치료 방법 |
| AU2024352066A1 (en) * | 2023-09-27 | 2026-04-09 | Changchun Genescience Pharmaceutical Co., Ltd. | New sirna, composition comprising same, and use |
| WO2025076595A1 (en) * | 2023-10-12 | 2025-04-17 | RAGE Biotech Pty Ltd | Rnai agents targeting rage |
| WO2025222258A1 (en) * | 2024-04-24 | 2025-10-30 | RAGE Biotech Pty Ltd | Methods of treating or preventing obstructive pulmonary disease |
| WO2025236048A1 (en) * | 2024-05-17 | 2025-11-20 | RAGE Biotech Pty Ltd | Methods of treating the effects of smoke |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US20020123476A1 (en) | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
| US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
| ATE330644T1 (de) | 1995-12-18 | 2006-07-15 | Angiotech Biomaterials Corp | Vernetzten polymerisatmassen und verfahren für ihre verwendung |
| DE69834038D1 (de) | 1997-07-01 | 2006-05-18 | Isis Pharmaceutical Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| JP2002537343A (ja) | 1999-02-23 | 2002-11-05 | アイシス・ファーマシューティカルス・インコーポレーテッド | 多重粒子製剤 |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| JP3837494B2 (ja) * | 2001-03-19 | 2006-10-25 | 国立大学法人金沢大学 | 可溶型ｒａｇｅタンパク質 |
| US7026121B1 (en) * | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| JP2008539698A (ja) * | 2005-04-29 | 2008-11-20 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 転写後レベルでの核酸発現調節のための方法および組成物 |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| JP2010233542A (ja) * | 2009-03-31 | 2010-10-21 | Kanazawa Univ | Ｒａｇｅ遺伝子の２種類のスプライシングバリアントを区別して増幅可能なプライマーセット及びプローブ |
| US20100303776A1 (en) * | 2009-04-16 | 2010-12-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for regulated expression of multiple nucleic acids |
| US9315298B2 (en) | 2011-08-25 | 2016-04-19 | Db Equipment As | Accessory bag having reinforced sidewalls and variable length |
| WO2019222693A1 (en) * | 2018-05-17 | 2019-11-21 | Lifesplice Pharma Llc | Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use |
| JP2022533358A (ja) | 2019-05-14 | 2022-07-22 | モナシュ ユニバーシティ | 終末糖化産物受容体ｒｎａのモジュレーター及び調節 |
-
2020
- 2020-05-07 JP JP2021568406A patent/JP2022533358A/ja active Pending
- 2020-05-07 MX MX2021013858A patent/MX2021013858A/es unknown
- 2020-05-07 CN CN202080044288.6A patent/CN114127288A/zh active Pending
- 2020-05-07 CA CA3140209A patent/CA3140209A1/en active Pending
- 2020-05-07 AU AU2020276337A patent/AU2020276337B2/en active Active
- 2020-05-07 SG SG11202112144RA patent/SG11202112144RA/en unknown
- 2020-05-07 WO PCT/AU2020/050449 patent/WO2020227758A1/en not_active Ceased
- 2020-05-07 BR BR112021022714A patent/BR112021022714A2/pt unknown
- 2020-05-07 EP EP20806464.2A patent/EP3969590A4/en active Pending
- 2020-05-07 KR KR1020217039458A patent/KR20220009971A/ko active Pending
-
2021
- 2021-08-25 US US17/411,932 patent/US11441148B2/en active Active
- 2021-11-11 IL IL288040A patent/IL288040A/en unknown
-
2022
- 2022-09-07 US US17/930,364 patent/US11674143B2/en active Active
-
2023
- 2023-05-01 US US18/310,289 patent/US12565656B2/en active Active
-
2025
- 2025-04-02 JP JP2025061149A patent/JP2025106369A/ja active Pending
- 2025-08-29 AU AU2025223886A patent/AU2025223886A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| DK2850186T3 (en) | COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION | |
| JP7049247B2 (ja) | 腎臓病の処置のための組成物と方法 | |
| EP2850190B1 (en) | Compositions and methods for modulating mecp2 expression | |
| JP6622214B2 (ja) | Ｓｏｄ−１発現を調節するための組成物 | |
| JP2022103192A (ja) | タウ発現を調節するための組成物 | |
| JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
| JP2016531570A (ja) | ユークロマチン領域を標的とするオリゴヌクレオチド | |
| JP2021527437A (ja) | Ｓｃｎ９ａ発現を調節するためのオリゴヌクレオチド | |
| JP2016528897A (ja) | Ｒｎａを調節するための組成物および方法 | |
| US20150141320A1 (en) | Compositions and methods for modulating gene expression | |
| JP2015523853A (ja) | Ａｔｐ２ａ２発現を調節するための組成物及び方法 | |
| JP2019500347A (ja) | 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法 | |
| JPWO2020227758A5 (https=) | ||
| TW202102676A (zh) | 調節atxn2表現之寡核苷酸 | |
| AU2022321898A1 (en) | Method | |
| CN117980479A (zh) | 用于治疗基于无义介导的rna衰变的病状和疾病的反义寡聚体 | |
| JP7604361B2 (ja) | 治療での使用及び方法 | |
| JP7788561B2 (ja) | アンチセンスオリゴヌクレオチド及びその使用 | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| KR101783444B1 (ko) | miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법 | |
| JP6934695B2 (ja) | 核酸医薬とその使用 | |
| JP2024519204A (ja) | 複数の標的を介して疼痛を処置するための治療組成物 | |
| CN116670276A (zh) | 用于通过多个靶标治疗疼痛的治疗组合物 | |
| CN115698290A (zh) | 用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法 |